Abstract
The mitochondrial enzyme manganese superoxide dismutase (MnSOD) has been shown to have two faces with regard to its role in tumor development. On the one side, it is well documented that overexpression of MnSOD slows down cancer cell growth, whereas on the other side MnSOD also has a metastasis-promoting activity. We set out to examine the role of MnSOD in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, thought to be a first-line tumor surveillance mechanism and failure to undergo apoptosis might contribute to metastasis formation. We show that overexpression of MnSOD at moderate levels is able to protect cells from TRAIL-induced apoptosis. While caspase-8 activation and Bid cleavage were not affected by MnSOD, we detected a marked decrease in caspase-3 activation pointing to a mitochondrial resistance mechanism. Indeed, we found that MnSOD-overexpressing cells showed reduced cytochrome c and no Smac/DIABLO release into the cytosol. The resulting lack of X-linked inhibitor of apoptosis (XIAP) inhibition by cytosolic Smac/DIABLO most likely caused the TRAIL resistance as RNAi against XIAP-rescued caspase-3 activity and TRAIL sensitivity. Our results show that reactive oxygen species are involved in TRAIL-induced Smac/DIABLO release and in TRAIL-triggered apoptosis. Hence, high levels of MnSOD, which decompose and neutralize these reactive oxygen species, might contribute to metastasis formation by allowing disseminated tumor cells to escape from TRAIL-mediated tumor surveillance. As part of TRAIL regimens, adjuvant treatment with XIAP inhibitors in the form of Smac/DIABLO mimetics or MnSOD inhibitors might be able to break TRAIL resistance of malignant tumor cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155–162.
Behrend L, Mohr A, Dick T, Zwacka RM . (2005). Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cells. Mol Cell Biol 25: 7758–7769.
Braeuer SJ, Buneker C, Mohr A, Zwacka RM . (2006). Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res 4: 715–728.
Buttke TM, Sandstrom PA . (1995). Redox regulation of programmed cell death in lymphocytes. Free Radic Res 22: 389–397.
Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ . (2002). Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168: 1356–1361.
Cullen JJ, Weydert C, Hinkhouse MM, Ritchie J, Domann FE, Spitz D et al. (2003). The role of manganese superoxide dismutase in the growth of pancreatic adenocarcinoma. Cancer Res 63: 1297–1303.
Culotta VC, Yang M, O’Halloran TV . (2006). Activation of superoxide dismutases: putting the metal to the pedal. Biochim Biophys Acta 1763: 747–758.
Davis AR, Wivel NA, Palladino JL, Tao L, Wilson JM . (2001). Construction of adenoviral vectors. Mol Biotechnol 18: 63–70.
Deryugina EI, Quigley JP . (2006). Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9–34.
Duiker EW, Mom CH, de Jong S, Willemse PH, Gietema JA, van der Zee AG et al. (2006). The clinical trail of TRAIL. Eur J Cancer 42: 2233–2240.
Egeblad M, Werb Z . (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161–174.
Fulda S, Wick W, Weller M, Debatin KM . (2002). Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8: 808–815.
Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ et al. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285–296.
Izeradjene K, Douglas L, Tillman DM, Delaney AB, Houghton JA . (2005). Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines. Cancer Res 65: 7436–7445.
Izutani R, Asano S, Imano M, Kuroda D, Kato M, Ohyanagi H . (1998). Expression of manganese superoxide dismutase in esophageal and gastric cancers. J Gastroenterol 33: 816–822.
Janssen AM, Bosman CB, Kruidenier L, Griffioen G, Lamers CB, van Krieken JH et al. (1999). Superoxide dismutases in the human colorectal cancer sequence. J Cancer Res Clin Oncol 125: 327–335.
Kahl R, Kampkotter A, Watjen W, Chovolou Y . (2004). Antioxidant enzymes and apoptosis. Drug Metab Rev 36: 747–762.
Karin M, Greten FR . (2005). NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749–759.
Lam EW, Zwacka R, Engelhardt JF, Davidson BL, Domann Jr FE, Yan T et al. (1997). Adenovirus-mediated manganese superoxide dismutase gene transfer to hamster cheek pouch carcinoma cells. Cancer Res 57: 5550–5556.
Lee MW, Park SC, Kim JH, Kim IK, Han KS, Kim KY et al. (2002). The involvement of oxidative stress in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in HeLa cells. Cancer Lett 182: 75–82.
Lewis A, Du J, Liu J, Ritchie JM, Oberley LW, Cullen JJ . (2005). Metastatic progression of pancreatic cancer: changes in antioxidant enzymes and cell growth. Clin Exp Metastasis 22: 523–532.
Li JJ, Oberley LW . (1997). Overexpression of manganese-containing superoxide dismutase confers resistance to the cytotoxicity of tumor necrosis factor alpha and/or hyperthermia. Cancer Res 57: 1991–1998.
Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG . (2004). A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 305: 1471–1474.
Liotta LA, Stetler-Stevenson WG . (1990). Metalloproteinases and cancer invasion. Semin Cancer Biol 1: 99–106.
Malafa M, Margenthaler J, Webb B, Neitzel L, Christophersen M . (2000). MnSOD expression is increased in metastatic gastric cancer. J Surg Res 88: 130–134.
Mantymaa P, Siitonen T, Guttorm T, Saily M, Kinnula V, Savolainen ER et al. (2000). Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol 108: 574–581.
Mohr A, Zwacka RM, Jarmy G, Buneker C, Schrezenmeier H, Dohner K et al. (2005). Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. Oncogene 24: 2421–2429.
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C . (1991). A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271–279.
Nozoe T, Honda M, Inutsuka S, Yasuda M, Korenaga D . (2003). Significance of immunohistochemical expression of manganese superoxide dismutase as a marker of malignant potential in colorectal carcinoma. Oncol Rep 10: 39–43.
Oberley LW . (2005). Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed Pharmacother 59: 143–148.
Papa S, Bubici C, Zazzeroni F, Pham CG, Kuntzen C, Knabb JR et al. (2006). The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ 13: 712–729.
Smirnov AS, Ruzov AS, Budanov AV, Prokhortchouk AV, Ivanov AV, Prokhortchouk EB . (2001). High constitutive level of NF-kappaB is crucial for viability of adenocarcinoma cells. Cell Death Differ 8: 621–630.
Spitz DR, Oberley LW . (1989). An assay for superoxide dismutase activity in mammalian tissue homogenates. Anal Biochem 179: 8–18.
Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H et al. (2002). Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 195: 161–169.
Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F et al. (1997). Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386: 517–521.
Toh Y, Kuninaka S, Oshiro T, Ikeda Y, Nakashima H, Baba H et al. (2000). Overexpression of manganese superoxide dismutase mRNA may correlate with aggressiveness in gastric and colorectal adenocarcinomas. Int J Oncol 17: 107–112.
Toruner M, Fernandez-Zapico M, Sha JJ, Pham L, Urrutia R, Egan LJ . (2006). Antianoikis effect of nuclear factor-kappaB through up-regulated expression of osteoprotegerin, BCL-2, and IAP-1. J Biol Chem 281: 8686–8696.
Vigneswaran N, Wu J, Nagaraj N, Adler-Storthz K, Zacharias W . (2005). Differential susceptibility of metastatic and primary oral cancer cells to TRAIL-induced apoptosis. Int J Oncol 26: 103–112.
Wajant H . (2006). CD95L/FasL and TRAIL in tumour surveillance and cancer therapy. Cancer Treat Res 130: 141–165.
Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ . (1999). The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119–127.
Wenk J, Brenneisen P, Wlaschek M, Poswig A, Briviba K, Oberley TD et al. (1999). Stable overexpression of manganese superoxide dismutase in mitochondria identifies hydrogen peroxide as a major oxidant in the AP-1-mediated induction of matrix-degrading metalloprotease-1. J Biol Chem 274: 25869–25876.
Wong GH, Elwell JH, Oberley LW, Goeddel DV . (1989). Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 58: 923–931.
Zhang HJ, Zhao W, Venkataraman S, Robbins ME, Buettner GR, Kregel KC et al. (2002). Activation of matrix metalloproteinase-2 by overexpression of manganese superoxide dismutase in human breast cancer MCF-7 cells involves reactive oxygen species. J Biol Chem 277: 20919–20926.
Zhang L, Fang B . (2005). Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12: 228–237.
Zwacka RM, Dudus L, Epperly MW, Greenberger JS, Engelhardt JF . (1998a). Redox gene therapy protects human IB-3 lung epithelial cells against ionizing radiation-induced apoptosis. Hum Gene Ther 9: 1381–1386.
Zwacka RM, Zhou W, Zhang Y, Darby CJ, Dudus L, Halldorson J et al. (1998b). Redox gene therapy for ischemia/reperfusion injury of the liver reduces AP1 and NF-kappaB activation. Nat Med 4: 698–704.
Acknowledgements
This work was supported by an Emmy-Noether grant from the Deutsche Forschungsgemeinschaft, ZW60/2-4 (RMZ), a Marie Curie Excellence Grant MEXT-CT-2006-042731 (RMZ) and by the NUIG Millennium Research Fund (RMZ). Furthermore, AM was supported by an HRB post-doctoral fellowship (PD/2006/26). We thank Claudia Cremers for technical assistance.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Mohr, A., Büneker, C., Gough, R. et al. MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release. Oncogene 27, 763–774 (2008). https://doi.org/10.1038/sj.onc.1210673
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210673
Keywords
This article is cited by
-
Differentiation-Dependent Effects of a New Recombinant Manganese Superoxide Dismutase on Human SK-N-BE Neuron-Like Cells
Neurochemical Research (2019)
-
Caspase-10: a molecular switch from cell-autonomous apoptosis to communal cell death in response to chemotherapeutic drug treatment
Cell Death & Differentiation (2018)
-
TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill
BMC Cancer (2015)
-
Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects
Cell Death & Disease (2013)
-
Mitochondrial proteomics of nasopharyngeal carcinoma metastasis
BMC Medical Genomics (2012)